{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=73",
    "query": {
      "intervention": "cohort 4",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T18:06:18.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02309580",
      "title": "Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Relapsed and Refractory T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-01",
      "completion_date": "2023-05-08",
      "has_results": false,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 2,
      "location_summary": "New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309580"
    },
    {
      "nct_id": "NCT00920088",
      "title": "Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "darunavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "Flurbiprofen",
          "type": "DRUG"
        },
        {
          "name": "GSK2248761",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-06",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-11-03",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920088"
    },
    {
      "nct_id": "NCT06116786",
      "title": "A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "JNJ-86974680",
          "type": "DRUG"
        },
        {
          "name": "Cetrelimab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Johnson & Johnson Enterprise Innovation Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2023-11-27",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 7,
      "location_summary": "Newnan, Georgia • Hackensack, New Jersey • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06116786"
    },
    {
      "nct_id": "NCT04125186",
      "title": "A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nocturnal Polyuria"
      ],
      "interventions": [
        {
          "name": "Baseline EpiNP survey",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bladder diary",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Testing of EpiNP baseline survey, bladder diary and a qualitative interview",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "No other intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 10190,
      "start_date": "2019-07-22",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04125186"
    },
    {
      "nct_id": "NCT05890105",
      "title": "A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "PF-07853578",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2023-06-02",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05890105"
    },
    {
      "nct_id": "NCT01390818",
      "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MSC1936369B (pimasertib)",
          "type": "DRUG"
        },
        {
          "name": "SAR245409 (PI3K and mTOR inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 146,
      "start_date": "2011-05",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01390818"
    },
    {
      "nct_id": "NCT07358260",
      "title": "B7-H3.CD28Z.CART in Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumor",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "B7-H3.CD28Z.CART",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Robbie Majzner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "9 Months to 30 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-08-24",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07358260"
    },
    {
      "nct_id": "NCT00996060",
      "title": "Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Hydralazine and Valproic Acid: Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine and Valproic Acid: Cohort 0",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine and Valproic Acid: Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine and Valproic Acid: Cohort 3",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine and Valproic Acid: Cohort 4",
          "type": "DRUG"
        },
        {
          "name": "Hydralazine and Valproic Acid: Cohort 5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2008-07",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996060"
    },
    {
      "nct_id": "NCT06679959",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Weight Management"
      ],
      "interventions": [
        {
          "name": "ASC30 Injection, for subcutaneous use or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascletis Pharma (China) Co., Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 115,
      "start_date": "2024-09-16",
      "completion_date": "2026-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679959"
    },
    {
      "nct_id": "NCT01621490",
      "title": "PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2012-09-27",
      "completion_date": "2018-10-25",
      "has_results": true,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-11-21T18:06:18.263Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01621490"
    }
  ]
}